The role of endometrial B cells in normal endometrium and benign female reproductive pathologies: a systematic review
Authors: Shen Mengni , O’Donnell Elizabeth , Leon Gabriela , Kisovar Ana , Melo Pedro , Zondervan Krina , Granne Ingrid , Southcombe Jennifer 
Published: December 2021

STUDY QUESTION

What are the similarities and differences in endometrial B cells in the normal human endometrium and benign reproductive pathologies?

SUMMARY ANSWER

Endometrial B cells typically constitute &lt;5% of total endometrial CD45+ lymphocytes, and no more than 2% of total cells in the normal endometrium, and while their relative abundance and phenotypes vary in benign gynaecological conditions, current evidence is inconsistent.

WHAT IS KNOWN ALREADY

B cells are vitally important in the mucosal immune environment and have been extensively characterized in secondary lymphoid organs and tertiary lymphoid structures (TLSs), with the associated microenvironment germinal centre. However, in the endometrium, B cells are largely overlooked, despite the crucial link between autoimmunity and reproductive pathologies and the fact that B cells are present in normal endometrium and benign female reproductive pathologies, scattered or in the form of lymphoid aggregates (LAs). A comprehensive summary of current data investigating B cells will facilitate our understanding of endometrial B cells in the endometrial mucosal immune environment.

STUDY DESIGN, SIZE, DURATION

This systematic review retrieved relevant studies from four databases (MEDLINE, EMBASE, Web of Science Core Collection and CINAHL) from database inception until November 2021.

PARTICIPANTS/MATERIALS, SETTING, METHODS

The search strategy combined the use of subject headings and relevant text words related to ‘endometrium’, ‘B cells’ and B-cell derivatives, such as ‘antibody’ and ‘immunoglobulin’. Non-benign diseases were excluded using cancer-related free-text terms, and searches were limited to the English language and human subjects. Only peer-reviewed research papers were included. Each paper was graded as ‘Good’, ‘Fair’ or ‘Poor’ quality based on the NEWCASTLE-OTTAWA quality assessment scale. Only ‘Good’ quality papers were included.

MAIN RESULTS AND THE ROLE OF CHANCE

Twenty-seven studies met the selection criteria and were included in this review: 10 cross-sectional studies investigated B cells in the normal endometrium; and 17 case–control studies compared the characteristics of endometrial B cells in control and benign female reproductive pathologies including endometritis, endometriosis, infertility, abnormal uterine bleeding, endometrial polyps and uterine fibroids. In all studies, B cells were present in the endometrium, scattered or in the form of LAs. CD20+ B cells were more abundant in patients with endometritis, but the data were inconsistent as to whether B-cell numbers were increased in endometriosis and patients with reproductive pathologies.

LIMITATIONS, REASONS FOR CAUTION

Although only ‘good’ quality papers were included in this systematic review, there were variations in patients’ age, diagnostic criteria for different diseases and sample collection time among included studies. Additionally, a large number of the included studies only used immunohistochemistry as the identification method for endometrial B cells, which may fail to provide an accurate representation of the numbers of endometrial B cells.

WIDER IMPLICATIONS OF THE FINDINGS

Histological studies found that endometrial B cells are either scattered or surrounded by T cells in LAs: the latter structure seems to be under hormonal control throughout the menstrual cycle and resembles TLSs that have been observed in other tissues. Further characterization of endometrial B cells and LAs could offer insights to endometrial B-cell function, particularly in the context of autoimmune-associated pathologies, such as endometriosis. Additionally, clinicians should be aware of the limited value of diagnosing plasma cell infiltration using only CD138.

STUDY FUNDING/COMPETING INTEREST(S)

This study was funded by Finox Biotech. The authors have no conflicts of interest to declare.

PROSPERO REGISTRATION NUMBER

This systematic review was registered in PROSPERO in January 2020 (PROSPERO ID: CRD42020152915).